Literature DB >> 1847659

Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator.

J Jankun1, V M Maher, J J McCormick.   

Abstract

To determine whether a relationship exists among urokinase plasminogen activator (u-PA) activity, tissue plasminogen activator (t-PA) activity, and the malignant transformation of human fibroblasts, we measured receptor-bound and secreted u-PAs and t-PA activity in fibroblast cell strains of a unique cell lineage and compared the results with the values obtained in human fibrosarcoma-derived cell lines and control cell lines. The lineage consists of four nonmalignant, infinite life span cell strains, clonally derived from a finite life span, neonatal foreskin-derived cell line or one of its derivatives and 10 malignant cell strains clonally derived from that same derivative. Seven of the latter were malignantly transformed by K-, H-, or N-ras oncogene transfection, two were obtained following carcinogen treatment, and one arose spontaneously. All 10 malignant strains in this lineage exhibited significantly higher levels of activity of receptor-bound u-PA than was found in the cell strain from which they arose or the nonmalignant cell strains derived from it. The ras oncogene-transformed malignant strains also exhibited significantly higher levels of activity of receptor-bound t-PA than their cell strain of origin. The other three malignant strains showed undetectable levels, consistent with their attaining the malignant state by an alternate process. The five fully malignant fibrosarcoma-derived cell lines tested also showed high levels of receptor-bound u-PA and t-PA. The majority (greater than or equal to 80%) of the nonmalignant control cell lines did not do so. The 10 malignant cell strains in the lineage also exhibited higher levels of activity of secreted high molecular weight u-PA or t-PA than did their cell strain of origin and the nonmalignant cell strains derived from it, as did the malignant fibrosarcoma-derived cell lines. The data suggest that the malignant state of human fibroblasts is always associated with high levels of activity of receptor-bound u-PA, and in addition cells transformed to the malignant state are very likely to exhibit high levels of receptor-bound t-PA and secreted forms of plasminogen activators.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847659

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.

Authors:  Neelesh Sharma; Maher Saifo; Ila R Tamaskar; Ramkumar Bhuvaneswari; Terry Mashtare; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2010-12

2.  Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.

Authors:  D F Alonso; E F Farías; V Ladeda; L Davel; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.

Authors:  H Allgayer; H Wang; S Shirasawa; T Sasazuki; D Boyd
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

4.  Association between KRAS mutation and lung metastasis in advanced colorectal cancer.

Authors:  A A L Pereira; J F M Rego; V Morris; M J Overman; C Eng; C R Garrett; A T Boutin; R Ferrarotto; M Lee; Z-Q Jiang; P M Hoff; J-N Vauthey; E Vilar; D Maru; S Kopetz
Journal:  Br J Cancer       Date:  2014-12-23       Impact factor: 7.640

5.  Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.

Authors:  Patricia A Madureira; Alamelu G Bharadwaj; Moamen Bydoun; Katy Garant; Paul O'Connell; Patrick Lee; David M Waisman
Journal:  Oncotarget       Date:  2016-07-26

6.  Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report.

Authors:  Pan Yang; Wei-Liang Li; Jeff-X Zhou; Yu-Bo Yang; Xia-Xiang Jin
Journal:  J Med Case Rep       Date:  2017-09-27

Review 7.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

8.  Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts.

Authors:  Daniel M Appledorn; Kim-Hien T Dao; Sandra O'Reilly; Veronica M Maher; J Justin McCormick
Journal:  BMC Cancer       Date:  2010-01-12       Impact factor: 4.430

9.  S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.

Authors:  Moamen Bydoun; Andra Sterea; Henry Liptay; Andrea Uzans; Weei-Yuarn Huang; Gloria J Rodrigues; Ian C G Weaver; Hong Gu; David M Waisman
Journal:  Mol Oncol       Date:  2018-09-21       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.